ENDRA Life Sciences Faces Nasdaq Compliance Challenge

ENDRA Life Sciences ( (NDRA) ) has provided an announcement.

On May 27, 2025, ENDRA Life Sciences received a notice from Nasdaq indicating non-compliance with the minimum stockholders’ equity requirement of $2,500,000, as their equity was reported at $1,752,885. While this notice does not immediately affect the company’s stock listing, ENDRA has until July 11, 2025, to submit a compliance plan. If accepted, they could have until November 23, 2025, to meet the requirements. The company is exploring options to address this issue but faces uncertainty regarding the acceptance of their plan and potential delisting.

The most recent analyst rating on (NDRA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on ENDRA Life Sciences stock, see the NDRA Stock Forecast page.

Spark’s Take on NDRA Stock

According to Spark, TipRanks’ AI Analyst, NDRA is a Underperform.

ENDRA Life Sciences is currently facing significant financial and operational challenges, with no revenue generation and persistent losses. Despite some short-term technical momentum, the lack of profitability and unattractive valuation metrics weigh heavily on the stock’s potential. Immediate improvements in financial performance and strategic direction are crucial for enhancing its outlook.

To see Spark’s full report on NDRA stock, click here.

More about ENDRA Life Sciences

ENDRA Life Sciences Inc. operates in the medical technology industry, focusing on developing and commercializing imaging technologies for early disease detection and treatment monitoring.

Average Trading Volume: 171,107

Technical Sentiment Signal: Sell

Current Market Cap: $2.38M

For an in-depth examination of NDRA stock, go to TipRanks’ Stock Analysis page.